↓ Skip to main content

Dove Medical Press

Article Metrics

Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells

Overview of attention for article published in Breast cancer targets and therapy, December 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#2 of 185)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
17 news outlets
blogs
2 blogs
twitter
5 tweeters
facebook
5 Facebook pages

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
29 Mendeley
Title
Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells
Published in
Breast cancer targets and therapy, December 2016
DOI 10.2147/bctt.s124860
Pubmed ID
Authors

Matthew Cook, Yayun Liang, Cynthia Besch-Williford, Salman Hyder

Abstract

Most breast cancer-related deaths from triple-negative breast cancer (TNBC) occur following metastasis of cancer cells and development of tumors at secondary sites. Because TNBCs lack the three receptors targeted by current chemotherapeutic regimens, they are typically treated with extremely aggressive and highly toxic non-targeted treatment strategies. Women with TNBC frequently develop metastatic lesions originating from drug-resistant residual cells and have poor prognosis. For this reason, novel therapeutic strategies that are safer and more effective are sought. Luteolin (LU) is a naturally occurring, non-toxic plant compound that has proven effective against several types of cancer. With this in mind, we conducted in vivo and in vitro studies to determine whether LU might suppress metastasis of TNBC. In an in vivo mouse metastasis model, LU suppressed metastasis of human MDA-MB-435 and MDA-MB-231 (4175) LM2 TNBC cells to the lungs. In in vitro assays, LU inhibited cell migration and viability of MDA-MB-435 and MDA-MB-231 (4175) LM2 cells. Further, LU induced apoptosis in MDA-MB-231 (4175) LM2 cells. Relatively low levels (10 µM) of LU significantly inhibited vascular endothelial growth factor (VEGF) secretion in MDA-MB-231 (4175) LM2 cells, suggesting that it has the ability to suppress a potent angiogenic and cell survival factor. In addition, migration of MDA-MB-231 (4175) LM2 cells was inhibited upon exposure to an antibody against the VEGF receptor, KDR, but not by exposure to a VEGF165 antibody. Collectively, these data suggest that the anti-metastatic properties of LU may, in part, be due to its ability to block VEGF production and KDR-mediated activity, thereby inhibiting tumor cell migration. These studies suggest that LU deserves further investigation as a potential treatment option for women with TNBC.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 28 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 21%
Student > Bachelor 5 17%
Researcher 4 14%
Student > Doctoral Student 2 7%
Other 2 7%
Other 3 10%
Unknown 7 24%
Readers by discipline Count As %
Medicine and Dentistry 7 24%
Biochemistry, Genetics and Molecular Biology 6 21%
Agricultural and Biological Sciences 6 21%
Unspecified 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 1 3%
Unknown 7 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 140. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 February 2017.
All research outputs
#146,399
of 16,031,926 outputs
Outputs from Breast cancer targets and therapy
#2
of 185 outputs
Outputs of similar age
#5,707
of 388,680 outputs
Outputs of similar age from Breast cancer targets and therapy
#2
of 19 outputs
Altmetric has tracked 16,031,926 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 185 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 388,680 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.